Balyasny Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Balyasny Asset Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,900	Closed	-$318K	–	1939
2017 Q1	$306K	Buy	+3,900	New	+$241K	﹤0.01%	1403
2016 Q1	–	Sell	-106,059	Closed	-$6.54M	–	1676
2015 Q4	$6.54M	Sell	106,059 -125,597	-54%	-$8.84M	0.05%	454
2015 Q3	$12.9M	Buy	231,656 +181,656	+363%	+$11.4M	0.1%	282
2015 Q2	$3.05M	Buy	+50,000	New	+$2.85M	0.02%	688

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Balyasny Asset Management's KITE Position: Q2 2017 in Review

Balyasny Asset Management sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 3,900 shares — an estimated $318K sold.

Balyasny Asset Management first reported a position in KITE in Q2 2015 and held it in 4 quarters. The position peaked at $12.9M in Q3 2015. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

Balyasny Asset Management reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
Balyasny Asset Management sold 3,900 Kite Pharma, Inc. shares in Q2 2017, an estimated $318K.
Balyasny Asset Management first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 4 quarters.
Balyasny Asset Management's Kite Pharma, Inc. position peaked at $12.9M in Q3 2015.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Balyasny Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.